Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cesca Therapeutics to Announce Second Quarter Fiscal 2016 Results and Provide a Status Update to Investors on February 16, 2016
Globe Newswire

RANCHO CORDOVA, Calif., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal second quarter ended December 31, 2015 and provide a status update to investors on Tuesday, February 16, 2016.

Company’s Conference Call and Webcast
Management will host a conference call on Tuesday, February 16, 2016 at 2:00 PM Pacific (5:00 PM Eastern).

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, “Cesca”.  Mr. Robin Stracey, Chief Executive Officer and Mr. Michael Bruch, Chief Financial Officer will be on the call to discuss the second quarter results and other corporate events, followed by a Q&A session.  Participants are asked to call the assigned number approximately five minutes before the conference call begins. 

To listen to the audio webcast of the call during or after the event, please visit: http://services.choruscall.com/links/cesca160216.

Replay
A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted 10081105’.

About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapies that advance the safe and effective practice of regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. 

Contact:
Cesca Therapeutics Inc.
http://www.cescatherapeutics.com
Investor Contact: Kirin Smith, PCG Advisory Group
646-863-6519, or ir@cescatherapeutics.com
Media Contact: Sean Leous, PCG Advisory Group
646-863-8998 or sleous@pcgadvisory.com

Primary Logo

 Top of page